NextCure Revenue and Competitors

Location

$310M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NextCure's estimated annual revenue is currently $14.9M per year.(i)
  • NextCure's estimated revenue per employee is $155,000
  • NextCure's total funding is $310M.
  • NextCure's current valuation is $154.7M. (January 2022)

Employee Data

  • NextCure has 96 Employees.(i)
  • NextCure grew their employee count by -4% last year.

NextCure's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
General CounselReveal Email/Phone
3
SVPReveal Email/Phone
4
VP Program Management & PlanningReveal Email/Phone
5
VP, Discovery ResearchReveal Email/Phone
6
VP Human ResourcesReveal Email/Phone
7
SVP, Clinical and Translational DevelopmentReveal Email/Phone
8
Associate DirectorReveal Email/Phone
9
Director, Cell Culture DevelopmentReveal Email/Phone
10
Director, Technology TransferReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$29.5M18519%N/AN/A
#2
$137.1M4832%N/AN/A
Add Company

What Is NextCure?

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.

keywords:N/A

$310M

Total Funding

96

Number of Employees

$14.9M

Revenue (est)

-4%

Employee Growth %

$154.7M

Valuation

N/A

Accelerator

NextCure News

2022-04-17 - NextCure, Inc. (NASDAQ:NXTC) Given Consensus Rating of ...

Get NextCure alerts: Several institutional investors and hedge funds have recently made changes to their positions in NXTC. Geode Capital...

2022-04-13 - NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation. NextCure. April 19, 2022 ·5 min read.

2022-04-06 - In Conversation: Shannon Biermann, Senior Quality Control ...

NextCure is a clinical stage biopharmaceutical company that is developing novel “immunomedicines” to treat cancer and other immune-related diseases.

2021-10-19 - NextCure : Announces Three New Members of its Scientific Advisory Board

BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Eliza ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.2M962%N/A
#2
$33.6M104-1%N/A
#3
$30.7M1067%N/A
#4
$26.5M1116%N/A
#5
$36M1127%N/A